Fennec Pharmaceuticals Inc. (FENC)
| Market Cap | 344.94M +101.5% |
| Revenue (ttm) | 51.00M +65.0% |
| Net Income | -8.38M |
| EPS | -0.28 |
| Shares Out | 34.74M |
| PE Ratio | n/a |
| Forward PE | 24.42 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 194,341 |
| Open | 10.28 |
| Previous Close | 9.97 |
| Day's Range | 9.80 - 10.45 |
| 52-Week Range | 5.65 - 10.45 |
| Beta | 0.91 |
| Analysts | Strong Buy |
| Price Target | 15.14 (+52.47%) |
| Earnings Date | May 14, 2026 |
About FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of oto... [Read more]
Financial Performance
In 2025, Fennec Pharmaceuticals's revenue was $44.64 million, a decrease of -6.09% compared to the previous year's $47.54 million. Losses were -$9.74 million, 2134.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price target is $15.14, which is an increase of 52.47% from the latest price.
News
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside ...
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
PEDMARK, the only approved agent to prevent cisplatin-induced hearing loss, is expanding from pediatrics into the larger AYA market, driving record revenues and broader adoption. Ongoing real-world studies and global partnerships aim to unlock further growth and long-term exclusivity.
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that...
Fennec Pharmaceuticals Slides: Corporate presentation
Fennec Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Adherex Technologies Q1 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow ...
Fennec Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 73% year-over-year sales growth, driven by commercial expansion and strong demand in key cancer segments. Operational improvements led to record infusions and high conversion rates, while new clinical studies and international launches are set to support further growth.
Fennec Pharmaceuticals Earnings release: Q1 2026
Fennec Pharmaceuticals released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Fennec Pharmaceuticals Quarterly report: Q1 2026
Fennec Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 14, 2026.
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ...
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Proxy statement: Proxy filing
Fennec Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Fennec Pharmaceuticals Slides: Corporate presentation
Fennec Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigatio...
Fennec Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 sales and robust AYA growth drove a 50% revenue increase, supported by expanded teams, new clinical evidence, and a strengthened balance sheet. U.S. exclusivity for PEDMARK is secured through 2033, with major European launches and further growth expected in 2026.
Fennec Pharmaceuticals Annual report: Q4 2025
Fennec Pharmaceuticals has published its Q4 2025 annual report on March 24, 2026.
Fennec Pharmaceuticals Earnings release: Q4 2025
Fennec Pharmaceuticals released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75%...
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Me...
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on Dec...
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –
Fennec Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
PEDMARK, the only FDA-approved therapy for cisplatin-induced ototoxicity in pediatric and AYA patients, is expanding its market reach with strong sales growth, broad payer coverage, and new data supporting efficacy and safety. European and Japanese launches are underway, with ongoing efforts to expand indications and awareness.
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates o...